ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer

被引：0
|
作者：
Mc Leer, A. [1 ]
Duruisseaux, M. [2 ]
Pinsolle, J. [2 ]
Dubourg, S. [1 ]
Mondet, J. [1 ]
Phillips-Houlbracq, M. [2 ]
Magnat, N. [1 ]
Faure, J. [3 ]
Chatagnon, A. [3 ]
de Fraipont, F. [1 ]
Levra, M. Giaj [2 ]
Toffart, A. C. [2 ]
Ferretti, G. [4 ]
Brambilla, E. [5 ]
Hainaut, P. [1 ]
Moro-Sibilot, D. [2 ]
Lantuejoul, S. [5 ]
机构：
[1] Hop Michallon, CHU Grenoble, Canc Mol Genet Platform, La Tronche, France
[2] Hop Michallon, CHU Grenoble, Thorac Oncol, La Tronche, France
[3] Hop Michallon, CHU Grenoble, Mol Biol Platform, La Tronche, France
[4] Hop Michallon, CHU Grenoble, Radiol & Imaging Dept, La Tronche, France
[5] Hop Michallon, CHU Grenoble, Dept Pathol, La Tronche, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1336P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [32] Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Olmez, O. F.
    Bilici, A.
    Gursoy, P.
    Cubukcu, E.
    Sakin, A.
    Korkmaz, T.
    Cil, I.
    Cakar, B.
    Menekse, S.
    Demir, T.
    Acikgoz, O.
    Hamdard, J.
    PULMONOLOGY, 2023, 29 (06): : 478 - 485
  • [33] Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
    Tian, Yu
    Huang, Jia
    Li, Chongwu
    Jiang, Long
    Lin, Hao
    Lu, Peiji
    Luo, Qingquan
    Yang, Guocai
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [34] Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Davis, K. L.
    Kaye, J. A.
    Masters, E. T.
    Iyer, S.
    CURRENT ONCOLOGY, 2018, 25 (01) : E40 - E49
  • [35] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
  • [36] INCORPORATING CRIZOTINIB INTO CLINICAL PRACTICE AS A NEW STANDARD OF CARE (SOC) IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Soria, J.
    Blackhall, F.
    Solomon, B.
    Crino, L.
    Scagliotti, G.
    Bartlett, C. Huang
    Wilner, K.
    Ou, S. I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S64 - S65
  • [37] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
    Larkins, Erin
    Blumenthal, Gideon M.
    Chen, Huanyu
    He, Kun
    Agarwal, Rajiv
    Gieser, Gerlie
    Stephens, Olen
    Zahalka, Eias
    Ringgold, Kimberly
    Helms, Whitney
    Shord, Stacy
    Yu, Jingyu
    Zhao, Hong
    Davis, Gina
    McKee, Amye E.
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
  • [38] Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Peter N. Morcos
    Eveline Nueesch
    Felix Jaminion
    Elena Guerini
    Joy C. Hsu
    Walter Bordogna
    Bogdana Balas
    Francois Mercier
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 129 - 138
  • [39] Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
    Edmond Bendaly
    Anand A. Dalal
    Kenneth Culver
    Philip Galebach
    Iryna Bocharova
    Rebekah Foster
    Medha Sasane
    Alexander R. Macalalad
    Annie Guérin
    Advances in Therapy, 2017, 34 : 1673 - 1685
  • [40] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
12345